To Toci or Not to Toci for Coronavirus Disease 2019 (COVID-19): Is That Still the Question?
Clin Infect Dis
.
2021 Jul 15;73(2):e455-e457.
doi: 10.1093/cid/ciaa1133.
Authors
Guang-Shing Cheng
1
2
,
Joshua A Hill
2
3
4
Affiliations
1
Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington, USA.
2
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
3
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
4
Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
PMID:
32735642
PMCID:
PMC7454367
DOI:
10.1093/cid/ciaa1133
No abstract available
Keywords:
COVID-19; SARS-CoV-2; coronavirus; immunomodulatory; tocilizumab.
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19*
Humans
SARS-CoV-2
Substances
Antibodies, Monoclonal, Humanized